221 related articles for article (PubMed ID: 33734949)
21. Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections.
Hutton DW; Toy M; Salomon JA; Conners EE; Nelson NP; Harris AM; So S
Sex Transm Dis; 2022 Jul; 49(7):517-525. PubMed ID: 35312661
[TBL] [Abstract][Full Text] [Related]
22. Selective Hepatitis B Birth-Dose Vaccination in São Tomé and Príncipe: A Program Assessment and Cost-Effectiveness Study.
Hagan JE; Carvalho E; Souza V; Queresma Dos Anjos M; Abimbola TO; Pallas SW; Tevi Benissan MC; Shendale S; Hennessey K; Patel MK
Am J Trop Med Hyg; 2019 Oct; 101(4):891-898. PubMed ID: 31392947
[TBL] [Abstract][Full Text] [Related]
23. [Cost-effectiveness and cost-benefit analysis on strategy for preventing mother-to-child transmission of hepatitis B virus].
Cai YL; Zhang SX; Yang PC; Lin Y
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Jun; 37(6):846-51. PubMed ID: 27346114
[TBL] [Abstract][Full Text] [Related]
24. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
Hall EW; Weng MK; Harris AM; Schillie S; Nelson NP; Ortega-Sanchez IR; Rosenthal E; Sullivan PS; Lopman B; Jones J; Bradley H; Rosenberg ES
J Infect Dis; 2022 Sep; 226(6):1041-1051. PubMed ID: 35260904
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses.
Jakiche R; Borrego ME; Raisch DW; Gupchup GV; Pai MA; Jakiche A
Am J Med Sci; 2007 Jan; 333(1):26-34. PubMed ID: 17220691
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Utilization of Hepatitis B Virus-Positive Liver Donors for HBV-Negative Transplant Recipients.
Lee TC; Eckman MH; Shah SA
J Gastrointest Surg; 2021 Jul; 25(7):1760-1769. PubMed ID: 32728822
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making.
Tu HAT; de Vries R; Woerdenbag HJ; Li SC; Le HH; van Hulst M; Postma MJ
Value Health Reg Issues; 2012 May; 1(1):7-14. PubMed ID: 29702830
[TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of newborn hepatitis B immunization in Beijing.
Guo Y; Yang Y; Bai Q; Huang Z; Wang Z; Cai D; Li S; Man X; Shi X
Hum Vaccin Immunother; 2021 Apr; 17(4):1196-1204. PubMed ID: 33016814
[TBL] [Abstract][Full Text] [Related]
30. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
[TBL] [Abstract][Full Text] [Related]
31. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness.
Harris A; Yong K; Kermode M
Aust N Z J Public Health; 2001 Jun; 25(3):222-9. PubMed ID: 11494989
[TBL] [Abstract][Full Text] [Related]
32. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
Krahn M; Detsky AS
Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
[TBL] [Abstract][Full Text] [Related]
34. [Development of Markov models for economics evaluation of strategies on hepatitis B vaccination and population-based antiviral treatment in China].
Yang PC; Zhang SX; Sun PP; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):845-851. PubMed ID: 28738454
[No Abstract] [Full Text] [Related]
35. Economic evaluation of implementing a decentralised Hepatitis B virus diagnostic intervention under National Viral Hepatitis Control Programme in Tamil Nadu, South India.
Muniyandi M; Tyagi K; Singh M; Prakash V; Karikalan N; Senthilkumar S; Karthikeyan S; Krishnan R; Rajsekar K; Shanmugam V; Selvavinayagam TS
Trop Med Int Health; 2021 Mar; 26(3):374-384. PubMed ID: 33190357
[TBL] [Abstract][Full Text] [Related]
36. An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence.
Rafia R; Dodd PJ; Brennan A; Meier PS; Hope VD; Ncube F; Byford S; Tie H; Metrebian N; Hellier J; Weaver T; Strang J
Addiction; 2016 Sep; 111(9):1616-27. PubMed ID: 26990598
[TBL] [Abstract][Full Text] [Related]
37. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.
Hwang JP; Huang D; Vierling JM; Suarez-Almazor ME; Shih YT; Chavez-MacGregor M; Duan Z; Giordano SH; Hershman DL; Fisch MJ; Cantor SB
JCO Clin Cancer Inform; 2019 Mar; 3():1-12. PubMed ID: 30892921
[TBL] [Abstract][Full Text] [Related]
40. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
